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Abstract: Background: To investigate the prognostic value of pre-treatment neutrophil/lymphocyte
ratio (NLR) in patients treated with definitive radiotherapy (RT) for head and neck cancer.
Methods: We retrospectively analyzed 621 patients who received definitive RT for nasopharyngeal,
oropharyngeal, hypopharyngeal, and laryngeal cancer. An NLR cut-off value of 2.7 was identified
using a receiver operating characteristic curve analysis, with overall survival (OS) as an endpoint.
Results: The 5-year progression-free survival (PFS) and OS for all patients were 62.3% and 72.1%,
respectively. The patients with a high NLR (68%) had a significantly lower 5-year PFS and OS than
their counterparts with a low NLR (32%) (PFS: 39.2% vs. 75.8%, p < 0.001; OS: 50.9% vs. 83.8%,
p < 0.001). In a subgroup analysis according to primary site, a high NLR also correlated with a lower
PFS and OS, except in oropharyngeal cancer, where a high NLR only exhibited a trend towards lower
survival. In a multivariate analysis, a high NLR remained an independent prognostic factor for PFS
and OS. Conclusion: Head and neck cancer tends to be more aggressive in patients with a high NLR,
leading to a poorer outcome after RT. The optimal therapeutic approaches for these patients should
be reevaluated, given the unfavorable prognosis.
Keywords: head and neck cancer; radiotherapy; neutrophil/lymphocyte ratio; survival
1. Introduction
Currently, definitive radiotherapy (RT) is one of the main modalities used to treat locally advanced
head and neck cancer. However, patients exhibit varying degrees of RT response and may develop
recurrences even after a complete response. Although various clinical and molecular predictors of
treatment outcomes after definitive RT for head and neck cancer have been investigated, no clear
consensus regarding reliable predictive biomarkers has been reached.
Treatment outcomes are known to be affected by both tumor characteristics and host-related
factors, including age, sex, and performance status. Recent reports have also described close
associations of systemic inflammation with tumorigenesis and treatment outcomes [1,2], and several
laboratory markers associated with systemic inflammatory processes, including albumin, hemoglobin,
absolute white blood cell (WBC) count or WBC components, and platelet count, have been investigated
as prognostic and predictive markers in various types of cancer [3,4]. Inflammation plays a key role in
cancer physiology by promoting carcinogenesis, dedifferentiation, and primary tumor growth, and by
stimulating tumor cell proliferation by inhibiting apoptosis and increasing mitotic rates [5].
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Tumor–host interactions can induce systemic inflammatory responses that affect the numbers of
circulating WBCs and the neutrophil/lymphocyte ratio (NLR) in certain types of cancers [6]. Normal
NLR values are in the range of 0.78–3.53 in the general population [7]; high NLR values are associated
with poor outcomes not only in cancer patients but also in patients with cardiovascular disease [8–10].
To date, some studies of head and neck cancer have suggested an association of high NLR with a poor
prognosis. However, data regarding the prognostic significance of a high NLR are limited, especially
among patients undergoing definitive RT [11–13]. The antitumor immune response is thought to be
part of the ionizing radiation-induced tumor cell death process. Therefore, tumor shrinkage caused
by the host immune response may be a direct effect of radiation [14,15]. Accordingly, we postulated
that the host immune status, as reflected by the NLR, may predict recurrence after RT in head and
neck cancer patients. This study aimed to evaluate the relationships of pretreatment NLR and other
hematologic markers with tumor recurrence and survival in patients undergoing definitive RT for
head and neck cancer.
2. Materials and Methods
2.1. Patient Selection and Treatment Protocols
This study was approved by the institutional review board of the Gangnam Severance Hospital
(Protocol number: 3-2017-0387). We retrospectively reviewed the medical records of patients who
underwent definitive RT with or without concurrent chemotherapy for cancers of the head and
neck (including nasopharyngeal, oropharyngeal, hypopharyngeal, and laryngeal cancers) at our
institution between 2006 and 2015. Patients who underwent surgery before or after RT, received RT of
<30 Gy, had a distant metastasis at the initial diagnosis or previous history of other primary cancer,
and whose pre-RT common blood test results were unavailable were excluded. The remaining 621
patients included in the analysis were staged according to the 7th edition of the TNM classification
of the American Joint Committee on Cancer (AJCC). Human Papilloma Virus (HPV) infection status
was evaluated in oropharyngeal cancer patients. To assess HPV status of each tumor, we used
formalin-fixed, paraffin-embedded biopsy tissue to examine p16 expression, which is recognized as
a surrogate marker for HPV infection in the oropharynx. Details of this process are described in a
previous report of our institution [16].
Patients were treated with definitive RT alone, concurrent chemoradiotherapy (CCRT), or
induction chemotherapy followed by CCRT. The choice of treatment was determined by the primary
tumor and stage, risk factors, and/or the physicians’ discretion. External beam RT comprised either
3D-conformal RT or intensity-modulated RT (IMRT) and was administered 5 days per week in daily
fractions of 1.8–2.5 Gy to yield total doses to the primary tumor of 66–75 Gy.
Concurrent chemotherapy regimens included weekly cisplatin (DDP; 40 mg/m2); weekly
5-fluorouracil (5-FU) and cisplatin (FP; 750 mg/m2 and 20 mg/m2, respectively); and 5-FU, taxotere, and
cisplatin (TPF; 750 mg/m2, 70 mg/m2, and 75 mg/m2, respectively) every 3 weeks. The anti-epidermal
growth factor receptor mAb, cetuximab (Erbitux), was also used. The induction chemotherapy regimen
consisted of FP every 3 weeks for 3 cycles or TPF every 3 weeks for 2 cycles.
2.2. Hematologic Markers
The patients’ blood counts were evaluated prior to performing diagnostic procedures or
administering treatments. The WBC count, hemoglobin (Hb) level, absolute neutrophil count (ANC),
absolute lymphocyte count (ALC), platelet count, and albumin level were recorded. A diagnosis
of anemia was based on a hemoglobin level of <13 g/dL in men and <12 g/dL in women, and
hypoalbuminemia was defined as a serum albumin level <3.5 g/dL. Onodera’s prognostic nutritional
index (PNI) was calculated as 10 × Albumin + 0.005 × ALC.
The NLR was calculated as the neutrophil count divided by the lymphocyte count, and the
platelet/lymphocyte ratio (PLR) was calculated as the platelet count divided by the lymphocyte
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count. The optimum NLR cut-off values were identified via a receiver operating characteristic (ROC)
curve analysis, using overall survival (OS) as an end point (Supplement Figure S1), and patients were
categorized into high NLR (NLR ≥ 2.7) and low (NLR < 2.7) NLR groups.
2.3. Outcome Assessment
All patients were followed up for 4–6 weeks after RT, and subsequently at 3-month intervals
for the first and second years, 6-month intervals for the third year, and annually for the fourth and
fifth years. Progression was defined as regrowth of the primary tumor or the involvement of cervical
lymph node(s) (LN) or detection of any new lesion(s) in follow-up imaging studies. Progression-free
survival (PFS) was defined as the interval between the date of initial treatment to the detection of first
recurrence, death from any cause, or the last follow-up. OS was defined as the interval between the
date of initial treatment and death from any cause or the last follow-up.
2.4. Statistical Analysis
Categorical data were analyzed using Fisher’s exact test or the χ2 test. Continuous data were
compared between groups using the Mann–Whitney U test. The Kaplan–Meier method and log-rank
test were used to estimate and compare the PFS and OS rates. Hazard ratios (HRs) were obtained
using the cumulative survivor function and are reported with corresponding 95% confidence intervals
(CIs). Univariate and multivariate analyses of factors related to OS and PFS were conducted using the
Cox proportional hazards model, and multivariate analysis included all variables with p values < 0.05
in the univariate analysis. A p value < 0.05 was considered statistically significant. All analyses were
performed using IBM SPSS, version 20.0 (SPSS, Chicago, IL, USA).
3. Results
3.1. Patient and Treatment Characteristics
Table 1 presents the demographic and treatment characteristics of the 621 included patients, of
whom 425 (68.4%) and 196 (31.6%) were stratified into the low and high NLR groups, respectively.
Laryngeal cancer was the most frequent type of primary cancer in the low NLR group, whereas
nasopharyngeal cancer cases comprised the majority in the high NLR group. Patients with a high NLR
tended to have a more advanced clinical T classification and higher frequency of LN metastasis and a
significantly higher frequency of systemic chemotherapy (75.2% vs. 48.5%, p < 0.001) than those in the
low NLR group.
The groups did not differ significantly in terms of the use of IMRT. Of the 16 patients who did
not complete the planned course of RT, four (2.0%) and 12 (2.8%) belonged to the high and low NLR
groups, respectively (p = 0.787). However, more patients in the high NLR group received radiation
doses of ≥70 Gy (equivalent dose in 2 Gy fractions, α/β = 10), and the overall duration of RT tended
to be longer in this group.
Table 1. Patient characteristics.
Total Low NLR Group High NLR Group
Characteristics N = 621 (%) N = 425 (%) N = 196 (%) p Value
Age Median 60 60 60 0.166
(Range) (18–94) (18–89) (18–94)
Sex Male 514 (82.8) 365 (85.9) 149 (76.0) 0.002
Female 107 (17.2 60 (14.1) 47 (24.0)
Primary site Nasopharynx 192 (30.9) 119 (28.0) 73 (37.2) <0.001
Oropharynx 94 (15.1) 56 (13.2) 38 (19.4)
Hypopharynx 76 (12.2) 42 (9.9) 34 (17.3)
Larynx 259 (41.7) 208 (48.9) 51 (26.0)
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Table 1. Cont.
Total Low NLR Group High NLR Group
Characteristics N = 621 (%) N = 425 (%) N = 196 (%) p Value
T classification T1 259 (41.7) 206 (48.5) 53 (27.0) <0.001
T2 145 (23.3) 97 (22.8) 48 (24.5)
T3 94 (15.1) 52 (12.2) 42 (21.4)
T4 123 (19.8) 70 (16.5) 53 (27.0)
N classification N0 294 (47.3) 236 (55.5) 58 (29.6) <0.001
N1 87 (14.0) 56 (13.2) 31 (15.8)
N2 219 (35.3) 124 (29.2) 95 (48.5)
N3 21 (3.4) 9 (2.1) 12 (6.1)
Overall stage I 188 (30.3) 165 (38.8) 23 (11.7) <0.001
II 89 (14.3) 58 (13.6) 31 (15.8)
III 118 (19.0) 76 (17.9) 42 (21.4)
IVA 204 (32.9) 116 (27.3) 88 (44.9)
IVB 22 (3.5) 10 (2.4) 12 (6.1)
p16 UE b 56 (59.6) 31 (55.4) 25 (65.8) 0.529
(in oropharynx) negative 12 (1.9) 6 (10.7) 6 (15.8)
positive 26 (4.2) 19 (33.9) 7 (18.4)
Treatment RT alone 270 (43.5) 221 (52.0) 49 (25.0) <0.001
CCRT c 234 (37.7) 130 (30.6) 104 (53.1)
Induction + CCRT 117 (18.8) 74 (17.4) 43 (21.9)
RT modality 3D-CRT d 220 (35.4) 156 (36.7) 64 (32.7) 0.326
IMRT e 401 (64.6) 269 (63.3) 132 (67.3)
RT duration Median 46 45 47 <0.001
(days) (Range) (23–99) (23–99) (31–97)
Total dose <70 385 (61.0) 277 (64.6) 108 (53.5) 0.016
(EQD2Gy a, α/β = 10) ≥70 236 (37.4) 148 (34.5) 88 (43.6)
Abbreviations: a Equivalent dose in 2 Gy fractions, b unevaluable, c concurrent chemoradiotherapy, d 3-dimensional
conformal radiotherapy, e intensity modulated radiotherapy.
3.2. Hematologic Markers
Table 2 presents the values of the measured hematologic markers in all patients. The median
baseline WBC count, ANC, and ALC were 6800/µL, 3900/µL, and 1810/µL, respectively, and the WBC
and ANC values were significantly higher in the high NLR group. A higher proportion of patients
with leukocytosis (WBC count ≥9000/µL) was also observed in the high NLR group (31.7% vs. 7.8%
for low NLR, p < 0.001). The high NLR group also had higher platelet counts, which expectedly
yielded a higher PLR, and was more likely to present with anemia and hypoalbuminemia at the time
of diagnosis. Patients with a high NLR also had a significantly lower Onodera’s PNI (49.7 vs. 55 for
low NLR, p < 0.001).
Table 2. Hematologic markers.
Total low NLR Group High NLR Group
Characteristic N = 621 (%) N = 425 (%) N = 196 (%) p Value
WBC Median 6800 6300 7700 <0.001
(cells/µL) (range) (2000–21,100) (2000–10,700) (3700–21,100)
ANC a Median 3900 3460 5520 <0.001
(cells/µL) (range) (560–18,310) (940–6720) (560–18,300)
ALC b Median 1810 2040 1320 <0.001
(cells/ µL) (range) (160–3700) (700–3700) (160–2970)
Platelet Median 237 232 250 <0.001
(×103 cells/µL) (range) (14–600) (14–517) (40–600)
PLR c Median 131 116 194 <0.001
(range) (20–1733) 20–269 (26–1733)
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Table 2. Cont.
Total low NLR Group High NLR Group
Characteristic N = 621 (%) N = 425 (%) N = 196 (%) p Value
Hemoglobin Median 14 14.1 13.5 0.01
(mg/dL) (range) (51–15.1) (5.1–17.4) (8.3–51.1)
Anemia No 497 (80.0) 359 (84.5) 138 (70.4) <0.001
Yes 124 (20.0) 66 (15.5) 58 (29.6)
Albumin Median 4.4 4.4 4.3 <0.001
(g/dL) (range) (2.5–5.2) (2.7–5.2) (2.5–5.1)
Hypoalbuminemia UE e 69 (11.1) 49 (11.5) 20 (10.2) 0.02
(<3.3 g/dL) No 539 (86.8) 371 (87.3) 168 (85.7)
Yes 13 (2.1) 5 (1.2) 8 (4.1)
Onodera’s PNI d Median 53.1 55 49.7 <0.001
(range) (27.8–67.6) (32.8–67.6) (27.8–61.7)
Abbreviations: a Absolute neutrophil count, b absolute lymphocyte count, c platelet/ lymphocyte ratio, d prognostic
nutritional index, e unevaluable.
3.3. Survival Analysis
The patients were followed up for a median of 39 (range, 2–130) months. During the follow-up
period, 148 patients died and 156 experienced a recurrence. The 5-year PFS and OS rates for all patients
were 63.8% and 72.9%, respectively, and both rates were significantly lower in the high NLR group
than in the low NLR group (PFS: 39.2% vs. 75.8%, p < 0.001; OS: 50.9% vs. 83.8%, p < 0.001) (Figure 1).
In survival analyses stratified by early- (stage I–II) or advanced-stage disease (stage III–IV), a high
NLR remained significantly associated with a poor PFS and OS (Figure 2).
An additional subgroup analysis was performed after stratifying cases by the primary site
(nasopharynx, oropharynx, hypopharynx, and larynx). As shown in Figures 3 and 4, patients with
nasopharyngeal, hypopharyngeal, and laryngeal cancer and the high NLR group had poorer PFS
and OS rates. Among patients with oropharyngeal cancer, however, a high NLR status exhibited
only borderline significance in terms of 5-year PFS (42.0% vs. 54.0%, p = 0.059) (Figure 3B) and only
exhibited a trend with reduced OS (51.5% vs. 65.3%, p = 0.215) (Figure 4B).
We also conducted additional analysis according to the treatment scheme. Both PFS and OS were
significantly worse in high NLR patients receiving any type of treatment: Patients receiving RT alone,
5-year PFS 84.8% vs. 56.1%, p < 0.001 and OS 90.6% vs. 68.6%, p < 0.001; patients receiving CCRT,
5-year PFS 66.2% vs. 31.5%, p < 0.001 and OS 74.3% vs. 41.7%, p < 0.001; patients receiving induction
chemotherapy + CCRT, 5-year PFS 68.1% vs. 40.7%, p < 0.001 and OS 78.9% vs. 55.2%, p < 0.001.
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3.4. Analysis of Prognostic Factors
The results of univariate and multivariate analyses performed to identify prognostic factors for
PFS and OS are shown in Table 3. The multivariate analysis revealed significant associations of a high
NLR with poor PFS, an older age, and an advanced T classification. An elevated PLR was also found to
be associated with a poor PFS. An older age, advanced T classification, and high NLR were also found
to associate significantly with OS, and an elevated PLR exhibited a borderline significant association
with a poor OS. Primary hypopharyngeal cancer was associated with both a poor PFS and a poor OS.
A low albumin level (<3.3 g/dL) exhibited a negative trend with PFS, but not with OS. LN metastasis,
overall stage, leukocytosis (WBC count ≥9000/µL), anemia, and Onodera’s PNI were not identified as
prognostic factors for PFS or OS.
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Table 3. Prognostic factors for progression-free survival and overall survival.
Progression-Free Survival Overall Survival
Variable
Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis
HR 95%CI p HR 95%CI p HR 95%CI p HR 95%CI p
Age <60 1 1 1 1
≥60 1.61 1.22–2.12 0.001 1.54 1.08–2.19 0.017 2.40 1.71–3.37 <0.001 2.43 1.57–3.75 <0.001
Sex Male 1 1
Female 0.97 0.68–1.38 0.865 0.99 0.66–1.51 0.981
Primary site Nasopharynx 1 1 1 1
Oropharynx 1.78 1.21–2.62 0.003 1.04 0.67–1.61 0.859 2.29 1.44–3.62 <0.001 1.19 0.68–2.09 0.54
Hypophrynx 2.46 1.66–3.66 <0.001 1.88 1.17–3.01 0.009 3.41 2.13–5.44 <0.001 2.01 1.13–3.55 0.017
Larynx 0.63 0.44–0.91 0.012 1.07 0.65–1.76 0.786 0.74 0.48–1.15 0.181 0.97 0.49–1.90 0.924
T classification T1, 2 1 1 1 1
T3, 4 3.05 2.32–4.00 <0.001 2.03 1.37–3.00 <0.001 3.53 2.54–4.90 <0.001 2.39 1.48–3.86 <0.001
N classification N0 1 1 1 1
N1-3 2.78 2.06–3.77 <0.001 1.37 0.81–2.32 0.237 2.52 1.76–3.60 <0.001 1.11 0.60–2.04 0.749
Overall stage I-II 1 1 1 1
III-IVB 3.48 2.52–4.81 <0.001 1.44 0.78-2.67 0.244 3.76 2.53–5.60 <0.001 1.58 0.71–3.48 0.26
Treatment RT alone 1 1 1 1
CCRT e 2.83 2.06–3.90 <0.001 1.11 0.63–1.96 0.723 2.65 1.81–3.88 <0.001 1.02 0.53–1.98 0.951
Induction + CCRT 2.09 1.42–3.07 <0.001 0.77 0.41–1.46 0.425 1.98 1.25–3.13 0.003 0.85 0.38–1.64 0.519
RT modality 3D CRT f 1 1
IMRT g 1.26 0.95–1.68 0.107 1.19 0.86–1.66 0.298
Anemia No 1 1 1 1
Yes 2.25 1.69–3.00 <0.001 1.19 0.81–1.74 0.374 0.52 0.37–0.72 <0.001 0.96 0.63–1.45 0.829
WBC (cells/µL) <9000 1 1 1 1
(cells/µL) ≥9000 1.81 1.30–2.52 <0.001 0.93 0.61–1.43 0.748 1.62 1.08–2.42 0.021 0.73 0.43–1.23 0.233
ANC a <4000 1 1 1 1
(cells/µL) ≥4000 1.81 1.38–2.39 <0.001 0.75 0.51–1.10 0.142 2.02 1.45–2.81 <0.001 0.79 0.50–1.27 0.333
ALC b <2000 1 1 1 1
(cells/µL) ≥2000 0.61 0.45–0.82 0.001 1.10 0.72–1.68 0.672 0.55 0.38–0.79 0.001 1.10 0.64–1.89 0.72
Platelet <230 1 1
(103 cells/µL) ≥230 0.98 0.74–1.28 0.857 1.04 0.75–1.44 0.825
NLR <2.7 1 1 1 1
≥2.7 3.39 2.58–4.46 <0.001 4.10 2.66–6.34 <0.001 3.86 2.78–5.35 <0.001 4.63 2.69–7.94 <0.001
PLR c <150 1 1 1 1
≥150 1.79 1.36–2.36 0.001 1.57 1.20–2.06 0.03 1.96 1.42–2.74 0.001 1.24 0.96–2.40 0.096
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Table 3. Cont.
Progression-Free Survival Overall Survival
Variable
Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis
HR 95%CI p HR 95%CI p HR 95%CI p HR 95%CI p
Hypoalbuminemia No 1 1 1 1
Yes 4.18 2.20–7.93 <0.001 1.92 0.95–3.85 0.068 0.44 0.3–0.66 <0.001 1.54 0.69–3.42 0.288
Onodera’s PNI d <50 1 1 1 1
≥50 0.48 0.36–0.65 <0.001 0.80 0.53–1.23 0.316 0.44 0.31–0.63 <0.001 0.74 0.45–1.24 0.259
Abbreviations: a Absolute neutrophil count, b absolute lymphocyte count, c platelet/ lymphocyte ratio, d prognostic nutritional index, e concurrent chemoradiotherapy, f 3-dimensional
conformal radiotherapy, g intensity modulated radiotherapy.
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3.5. p16 Status and Hematologic Markers
We also evaluated the relationship of the p16 status with the levels of various hematologic
markers. This status was available for 38 of 94 patients with oropharyngeal cancer (40.4%). In total,
26 patients had p16-positive oropharyngeal cancer and 12 patients had p16-negative oropharyngeal
cancer. Patients with a positive p16 status tended to have a lower NLR than those with a negative
status (median NLR: 2.1 vs. 2.8, p = 0.103). In addition, the WBC count and ANC were lower in
p16-positive patients than in their p16-negative counterparts, although these differences were not
statistically significant (median WBC: 7100 vs. 8300/µL, p = 0.073; median ANC: 4000 vs. 5200/µL,
p = 0.119) (Supplement Figure S2).
Among the 26 patients with p16-positive oropharyngeal cancer, PFS and OS were not different
between the low and high NLR groups (5-year PFS 56.1% vs. 57.1%, p = 0.781 and 5-year OS 86.5% vs.
80.0%, p = 0.646). In patients with p16-negative oropharyngeal cancer (n = 12), PFS was significantly
lower in the high NLR group than in the low NLR group (5-year PFS 0% vs. 100%, p = 0.009), while OS
showed no difference, which may be due to the limited number of cases.
4. Discussion
During the past decade, various markers of systemic inflammation have been evaluated with the
aims of refining patient stratification to treatment and predictions of survival. Of these markers, the
NLR, which is derived from the ANC and ALC of a full blood count, is routinely available. Accordingly,
in this study, we evaluated the significance of the pre-treatment NLR in patients who received RT for
head and neck cancer and observed significant associations of a high NLR with disease recurrence and
OS in the patient sample.
As noted above, we stratified the patients into two groups according to NLR status and found
that those with a high NLR had a more advanced clinical stage and therefore more frequently received
concurrent chemotherapy with a higher total radiation dose and longer total duration of RT. Despite
this more aggressive treatment, however, patients with a high NLR were more likely to experience
unfavorable outcomes, and these results remained consistent regardless of disease stage. We further
found that adverse hematologic features, such as an elevated WBC, ANC, and platelet count as well as
anemia, hypoalbuminemia, and a low Onodera’s PNI, were more frequently observed in the high NLR
group. These findings suggest that certain types of tumors elicit an enhanced systemic inflammatory
response, which may reflect the aggressive nature of the tumor.
We also performed a subgroup analysis according to the primary site of head and neck carcinoma
and determined that a high NLR was significantly associated with a poorer PFS and OS among
patients with nasopharyngeal, hypopharyngeal, and laryngeal cancers. However, among patients
with oropharyngeal cancer, a high NLR was only borderline significant as a prognosticator of PFS and
exhibited a trend with OS. Other studies of oropharyngeal cancer have identified NLR as a significant
prognostic factor for disease control, and most have used a relatively higher NLR cut-off value
(≥5) [17,18] than those used for other primary sites in the head and neck [19,20]. Additionally, some
studies of oropharyngeal cancer have identified the prognostic significance of circulating neutrophil
and lymphocyte counts only for recurrence-free survival (RFS), but not for OS [21].
Our above findings may be attributable to the limited number of oropharyngeal cancer patients
in our study (n = 94) or to the effects of HPV infection. Previous studies suggested that HPV infection
might affect the distribution of WBC components and alter inflammatory responses in patients with
oropharyngeal cancer [11]. Huang et al. reported that HPV-positive patients had lower levels of
circulating neutrophil and monocyte counts when compared to their HPV-negative counterparts,
despite similar levels of lymphocyte counts [21]. In the HPV-positive cohort, a high neutrophil or
monocyte count was found to correlate with reductions in OS and RFS, whereas in the HPV-negative
cohort, the neutrophil and lymphocyte counts were not predictive of either survival parameter.
Another study also reported a significantly lower NLR among HPV-positive patients than among their
HPV-negative counterparts. Given these findings, we suggest that oropharyngeal cancer may exhibit
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behaviors or inflammatory responses that are distinct from those of head and neck cancers at other
primary sites. Although our study did not reveal significant differences in inflammatory markers
among oropharyngeal cancer patients according to p16 status, HPV infection might have altered the
WBC distribution and affected disease control and OS.
Some scientists have recommended that more accurate diagnostic tools are needed for risk
stratification according to HPV infection. Previous reports have suggested that HPV specific tests such
as DNA in situ hybridization and polymerase chain reaction should be used to confirm HPV status,
although p16 protein over-expression is very sensitive to the presence of transcriptionally-active HPV,
correlates strongly with patient outcomes, is widely available, and is easy to interpret [22]. Gupta et al.
also suggested that circulating HPV16 DNA in the plasma may be a clinically useful biomarker [23].
These biomarkers can be measured using a simple blood test, and the level of ctDNA is predictive of
an early treatment response. If used in combination with inflammatory markers, this technique will be
helpful in predicting a patient′s prognosis and determining an appropriate treatment plan.
As noted, NLR is an easily and routinely determined biomarker of systemic inflammation, and
in our study population a high NLR correlated strongly and independently with a poorer PFS and
OS. Previous studies have also identified a high NLR as an independent prognostic factor for many
other types of cancers, including colorectal cancer, renal cell cancer, pancreatic cancer, and head
and neck squamous cell carcinoma [2,24–28]. Although the tumorigenic mechanism underlying this
relationship with the NLR has not been clearly elucidated, it appears likely that increased levels of
several inflammatory cytokines contribute to a microenvironment that promotes carcinogenesis and
tumor progression [29]. Several growth factors, including epidermal growth factor, vascular endothelial
growth factor, and transforming growth factor-α, also contribute to the creation of microenvironments
supportive of angiogenesis and tumor proliferation [30]. Our results are therefore consistent with the
concept that a high NLR contributes to poor disease control by suppressing the cytolytic activities
of activated effector T cells and the peritumoral infiltration of immuno-suppressive cells such as
macrophages [31,32].
We further demonstrated that a higher PLR was associated with PFS in our multivariate analysis.
Again, the significance of interactions between platelets and the tumor microenvironment remains
somewhat unclear. The platelet count provides an additional index of systemic inflammation
elicited by the tumor and degranulation. This inflammation, together with the consequent release of
platelet-derived proangiogenic mediators within the tumor microvasculature, may also serve as an
important determinant of tumor growth [33–35].
This study had a few limitations. First, the study had a retrospective design and included various
primary sites of head and neck cancer. Additionally, patients in the high NLR group tended to have
more advanced-stage disease. However, the NLR remained a significant prognostic factor for survival
in the multivariate analysis, as well as in an additional analysis according to disease stage. Second, the
selection of treatment modalities and regimens was heterogeneous and was determined in accordance
with the primary site and physicians’ discretion. Third, we did not explore the association of LN
metastasis with patient outcomes because of the use of clinical stage and likelihood of upstaging for
LNs. Therefore, our findings should be interpreted cautiously. Nevertheless, this is one of the largest
studies to evaluate the prognostic significance of systemic inflammation in patients who underwent
RT for head and neck cancer, and we have revealed potential differences in the patients’ characteristics
and outcomes according to their NLR status. In addition, we observed different associations of the
NLR status among patients with oropharyngeal cancer versus those with other head and neck cancers,
which underscores the need for further studies of the relationship between HPV infection and the NLR.
In conclusion, the results of our large population study validate the suggested association of a high
NLR with poorer outcomes after adjusting for potential confounding factors. Although further studies
of the biological mechanisms underlying the relationship between inflammation and aggressiveness
are needed, our results suggest that a classification system based on pretreatment hematologic markers
could identify patients with a high risk of recurrence and poor survival.
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